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Financial dStable Long-Term Pulmonary Function after
Myeloablative Double Cord Blood Transplant
Filippo Milano,1, Jason W. Chien,1,2 Ivy Riffkin,1 Jonathan A. Gutman,3 Laura Newell,1,2
Steven A. Pergam,1,4 Colleen Delaney1,5Pulmonary dysfunction has been well described after myeloablative transplantation with conventional
allogeneic donors; however, whether the risk is similar after alternative donor transplantation with cord
blood as the stem cell source has not yet been investigated. We performed a retrospective analysis of
patients who underwent double cord blood transplantation after myeloablative conditioning. Pulmonary
function tests were performed pretransplantation and at day 80, 1 year, and 2 years posttransplantation,
with 56 patients included in the final analysis. No significant change from baseline with respect to the
mean values andmean change in pulmonary function test values were observed at 1 year posttransplantation.
The rate of lung function decline from baseline to 1 year posttransplantation was\5% in 75% patients; mildly
abnormal lung function was reported in 58% of the patients. The cumulative incidence of noninfectious
pulmonary complications was 9.7%. Future prospective studies are needed to confirm these findings.
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Cord blood (CB) transplantation (CBT) has been
used to successfully treat malignant and nonmalignant
disease in both adults and children [1,2]. The number
of CBTs performed annually continues to increase,
and more than 20,000 CBTs have been performed
worldwide since 1988. Despite the increased use of
CB for transplantation, very little is known about the
pulmonary complications occurring after CBT.
Pulmonary function tests (PFTs) are widely
performed before hematopoietic cell transplantation
(HCT) to screen for underlying respiratory abnormali-
ties and to provide baseline lung function measure-
ments. Decreases in spirometric measurements after
HCT are associated with increased mortality [3,4].
Previous studies have extensively evaluated the role of
conventional donor sources (peripheral blood versus
bone marrow) as risk factors for declining lung
function [5]; however, lung function decline after CBT
has not yet been investigated.
Pulmonary complications occur in 40%-60%of al-
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isclosure: See Acknowledgments on page 313.in more than one-third of cases [6]. Noninfectious pul-
monary complications, such as idiopathic pneumonia
syndrome (IPS) and cryptogenic organizing pneumo-
nia (COP), have become the most important respira-
tory complications leading to late morbidity and
decreased survival after HCT [7]. Recent reports sug-
gest that the risk of late-onset noninfectious pulmonary
complications after both single CBT and double CBT
(dCBT) was comparable after allogeneic sibling or
unrelated transplants [8].
To better characterize lung function in patients
undergoing myeloablative dCBT, we performed lon-
gitudinal analyses of PFTs before and after transplan-
tation and evaluated the incidence of noninfectious
pulmonary complications.PATIENTS AND METHODS
Patient Selection and Characteristics
This was a retrospective analysis of data collected
prospectively from patients who underwent myeloabla-
tive dCBT at the Fred Hutchinson Cancer ResearchCorrespondence and reprint requests: Filippo Milano, 1100
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2006 and December 2010. Patients without pretrans-
plantation PFTs were excluded from the analysis.
Patients received a CBT if they lacked an available
HLA-compatible related or an unrelated donor and if
a suitable single CB graft could not be found, as deter-
mined by institutional priority criteria. Selected CB
units were required to be matched to the recipient at
$4 of the 6 HLA loci based on intermediate-
resolution typing atHLA-A and -B and allele-level typ-
ing for HLA-DRB1; for dCBT recipients, units must
have been at least 3 of 6 HLA-matched to each other.
Myeloablative conditioning typically consisted of
cyclophosphamide 60 mg/kg i.v. daily for 2 days, total
body irradiation (TBI) 1320 or 1200 cGy, and fludar-
abine 25 mg/m2 i.v. daily for 3 days. A small group of
patients (n 5 11) received fludarabine 30 mg/m2 i.v.
daily for 5 days, treosulfan 14 g/m2 i.v. daily for 3
days, and a single fraction of TBI 200 cGy. All patients
received standard immunosuppressive prophylaxis for
graft-versus-host disease (GVHD) with cyclosporine-A
along with mycophenolate mofetil. Acute GVHD
was graded using standard criteria based on stages of
organ involvement and categorized as grade 0-IV [9].
The diagnosis and staging of chronic GVHD
(cGVHD) were based onNational Institutes of Health
(NIH) consensus criteria [10].Table 1. Demographic Characteristics of the dCBT
Recipients (n 5 56)
Age, years, median (IQR) 26.5 (17.2-41)
Sex, n (%)
Female 31 (55)
Male 25 (45)
Disease, n (%)
ALL 17 (30)
AML 29 (52)
CML 5 (9)
Other 5 (9)
Transplant type, n (%)
FLU/CY/TBI 1320 cGy 45 (80)
FLU/TREO/TBI 200 cGy 11 (20)
GVHD prophylaxis with cyclosporine/mycophenolate, n (%) 56 (100)
Recipient CMV serostatus, n (%)
Positive 39 (70)
Negative 17 (30)
Recipient weight, kg, median (IQR) 69.5 (55-78.4)
Smoker, n (%) 12 (21)
HLA disparity, n (%)*
4/6 35 (62)
5/6 14 (25)
6/6 7 (13)
Acute GVHD, n (%)
Grade 0-II 42 (75)
Grade III-IV 14 (25)
cGVHD, n (%) 24 (43)
TNCs infused,  107/kg, median (IQR)† 3.6 (2.7-4.5)
CD34+ cells infused,  106/kg, median (IQR)† 0.17 (0.14-25)
ALL indicates acute lymphoblastic leukemia;AML, acutemyelogenous leu-
kemia; CML, chronic myelogenous leukemia; CMV, cytomegalovirus; CY,
cytoxan; FLU, fludarabine; TNC, total nucleated cell; TREO, treosulfan.
*HLA matching reflects the worst-matched of the 2 units.
†Postthaw.Pulmonary Function Testing
All PFTswere performed at the SeattleCancerCare
Alliance, in accordancewithAmericanThoracic Society
guidelines [11], using the Sensormedics V-Max 22 with
Autobox 6200 (Sensormedics Co., Yorba Linda, CA).
Published equations for children and adults were used
to determine predicted values of forced expiratory vol-
ume in 1 second (FEV1), forced vital capacity (FVC), to-
tal lung capacity (TLC), and diffusion capacity of the
lung for carbon monoxide (DLCO) [12]. All DLCO
measurements were corrected for hemoglobin values
obtained closest to the time of determination of the dif-
fusion capacity [4]. All PFT values, except FEV1/vital
capacity (VC) ratio, were expressed as a percentage of
predicted values and assessed categorically. Day 80
PFTs were defined as PFTs obtained at day 80 6 20
days. One-year PFTs were defined as PFTs obtained
at day 365 6 20 days. PFT categories were defined as
normal ($80%), mildly abnormal (70%-79%), moder-
ately abnormal (60%-69%), and severely abnormal
(\60%). In accordance with NIH recommendations,
the lung function score (LFS) was calculated according
to the day 80 FEV1 and DLCO, each of which was
categorized as follows: ($80% 5 1; 70%-79% 5 2;
60%-69% 5 3; 50%-59% 5 4; 40%-49% 5 5; and
\40% 5 6) [12,13]. Scores for FEV1 and DLCO were
then summed and categorized as 0-3 based on NIH
recommendations (LFS score 2 5 category 0 [normal];LFS score 3-5 5 category 1 [mildly abnormal]; LFS
score 6-9 5 category 2 [moderately abnormal]; LFS
score 10-12 5 category 3 [severely abnormal]).
Pulmonary function abnormalities were categorized
into 2 major groups. Restrictive pattern was defined as
a TLC\80% of the predicted normal and FEV1/VC
$0.7 [13]. New airflow obstruction was defined accord-
ing to recently modified NIH guidelines [14] as FEV1/
VC \0.7, FEV1 #75%, and an FEV1 decrease of
$10% from pretransplantation value.
Clinically significant noninfectious syndromes
included IPS, defined as widespread alveolar injury in
the absence of active lower respiratory tract infection
after HCT [15]; diffuse alveolar hemorrhage, defined
as IPS with bronchioalveolar lavage showing progres-
sively bloodier return [16]; and biopsy-proven COP
[17,18]. Fungal infections were only considered if they
were probable or proven by standard guidelines [19].Statistical Methods
All statistical analyses were performed using Stata
11.0 (StataCorp, College Station, TX). A P value
\.05was considered statistically significant. For univar-
iate analyses, continuous variables were assessed using
a one-sample t test. A least squares regression line was
used to estimate the overall annualized rate of FEV1
decline from baseline to 1 year according to previously
described methods [14]. A cumulative incidence curve
Table 2. PFT Data Obtained Pretransplantation and at 80 Days, 1 Year, and 2 Years Posttransplantation
FEV1, Mean ± SD FVC, Mean ± SD FVC/VC, Mean ± SD TLC, Mean ± SD DLCO, Mean ± SD
Pretransplantation (n 5 56) 92.6 ± 15.0 98.4 ± 13.9 0.80 ± 0.07 98.0 ± 12.5 78.4 ± 15.2
Day 80 (n 5 55) 87.6 ± 13.1 92.4 ± 13.1 0.80 ± 0.08 93.7 ± 11.8 71.4 ± 15.2
1 year (n 5 36) 88.9 ± 12.8 93.3 ± 17.7 0.84 ± 1.01 93.7 ± 14.6 73.3 ± 17.9
2 years (n 5 20) 94.1 ± 15.0 91.8 ± 11.6 0.87 ± 0.06 102.3 ± 16.2 77.1 ± 16.3
Biol Blood Marrow Transplant 18:309-329, 2012 311Pulmonary Function after Cord Blood Transplantationwas used to estimate the incidence of pulmonary com-
plications, with death considered a competing risk.RESULTS
Patient Characteristics
A total of 76 consecutive patients underwent
myeloablative dCBT between January 1, 2006, and
December 31, 2010. Twenty patients (26%) were
excluded because they either died before the day 80
PFT evaluation (n5 17) or did not have pretransplanta-
tionPFTs performed (n5 9). All of the patientswithout
pretransplantation PFTs were children. Among the ex-
cluded patients, only 1 deathwas attributed to noninfec-
tious pulmonary complications. Fifty-six patients were
included in the final analysis. Patient, transplantation,
and graft characteristics are summarized in Table 1.
The median patient age was 26.5 years (interquartile
range [IQR], 17.2-41 years), and mean duration of
follow-upwas 446 days (IQR, 246-959 days). Eleven pa-
tients (19%) received a non–TBI-based conditioning
regimen. PFTs were done at the scheduled time point
regardless of the previous development of both infec-
tious and noninfectious pulmonary complications. At
day 80, all but 1 patient had PFT results. Thirty-six pa-
tients (64%)hadPFT results at 1 year, and 20 (36%)had
PFT results at 2 years. Among the 20 patients without
PFTs at 1 year, 16 died before the 1-year follow-up,
and 4 had less than 1 year of follow-up.
PFTs
Table 2 summarizes the distribution and the mean
values of the PFT data collected pretransplantation
and at day 80, 1 and 2 years posttransplantation. PFTs
were done at the scheduled time point regardless of
the previous development of both infectious and nonin-
fectious pulmonary complications. At day 80, all mean
PFT values except FEV1/VC ratio were significantly
lower than the baseline values (Table 3). At 1 year there
was no significant decline in mean FEV1, FVC, andTable 3. Changes in PFT Parameters from Baseline up to 2 Years P
FEV1 FVC
Mean ± SD P Value Mean ± SD P Value
Pretransplantation — — — —
Day 80 posttransplantation 26.2 ± 17.5 .0008 26.8 ± 15.7 .0001
1 year posttransplantation 20.1 ± 11.8 .56 22.6 ± 18.6 .17
2 years posttransplantation 0.46 ± 25.3 .52 23.8 ± 13.9 .23TLCvalues frombaseline; onlyDLCOwas significantly
lower (P5 .001); however, at 2 years DLCO improved
significantly from the earlier decline. Similar results
were observed when the patients treated with high-
dose TBI and those treated with low-dose TBI were an-
alyzed separately (data not shown). The FEV1/VC ratio
was significantly higher thanbaseline at both 1 year (P5
.007) and2 years (P5 .03)posttransplantation (Table 3).
As shown in Figure 1, the rate of FEV1 decline, as
measured by the annualized rate of FEV1 decrease dur-
ing the first year after HCT, was\5% in 75% patients,
with only 1 patient experiencing a decline of.20% from
baseline. That patient had a documented pulmonary
fungal infection, which might have accounted for this
decline. Evaluation of the LFS before transplantation
and at 1 year posttransplantation revealed an LFS of
0 in 25% of patients and an LFS of 1 in 58% (Table 4).
No patient had an LFS of 3.
Development of Airflow Obstruction,
Restrictive Pattern, and Infectious and
Noninfectious Pulmonary Complications
None of the patients included in this analysis had
a history of pulmonary complications on arrival for
transplantation at our center. Neither airflow obstruc-
tion nor restrictive pattern was observed in any of the
patients with evaluable PFT data at 1 year after trans-
plantation. Three patients (5%) developed COP, and
1 patient was diagnosed with IPS (2%). In 2 of the 3 pa-
tients with COP, the obstructive pattern was tempo-
rary, resolving completely after a short course of
corticosteroid therapy. The remaining 2 patients with
noninfectious pulmonary complications (1 with COP
and with 1 IPS) died secondary to infectious complica-
tions, at day 144 and day 190, respectively. The cumu-
lative incidence of all noninfectious pulmonary
complications, including the patients who died at day
40 from diffuse alveolar hemorrhage, was 9.7% (95%
confidence interval [CI], 3.4%-19.7%) (Figure 2).
In 15 patients, pulmonary infection occurred during
the first 2 years posttransplantation, with a cumulativeosttransplantation
FVC/VC TLC DLCO
Mean ± SD P Value Mean ± SD P Value Mean ± SD P Value
— — — — — —
0.2 ± 5.9 .73 25.0 ± 9.2 .0003 28.0 ± 12.4 <.0001
3.7 ± 7.8 .007 21.6 ± 9.7 .32 27.6 ± 12.4 .001
4.5 ± 8.9 .03 1.2 ± 12.1 .65 24.3 ± 13.4 .20
Figure 2. Cumulative incidence of infectious and noninfectious pulmo-
nary complications.
Figure 1. Annualized rate of FEV1 decline from pretransplantation to
1 year posttransplantation, categorized as\5%, 5%-10%, 5%-15%, or
.20% per year.
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Seven of these 7 patients either had developed coinfec-
tion during their primary episode (n 5 5) and/or had
multiple respiratory pathogens detected at different
time points during follow-up (n 5 4). Viral agents
were detected most frequently (n 5 12; 4 respiratory
syncytial virus, 2 adenovirus, 2 cytomegalovirus, 1meta-
pneumovirus, 2 parainfluenza, and 1 rhinovirus), fol-
lowed by fungal pathogens (n 5 11; 9 Aspergillus
fumigatus and 2 Mucorales) and bacterial agents (n 5
4; 2 Klebsiella pneumonia and 2 Pseudomonas aeruginosa).DISCUSSION
To our knowledge, this study is the first to report
on posttransplantation lung function after dCBT.
For this analysis, we used a complete set of PFTs, as
well as an annualized rate of decline and LFS, to accu-
rately describe lung function after dCBT. Although we
were unable to assess lung function decline in patients
who died before follow-up PFTs, 64% of the patients
in this study had PFTs at 1 year posttransplantation.
This study demonstrates that patients undergoing
myeloablative dCBT maintained stable lung function
overall. Although an initial decline in lung function
was observed in the first 100 days posttransplantation,
lung function returned to baseline level by 1 year, at
which point 75% of the patients had a\5% decline
in FEV1. Underscoring the importance of our find-
ings, previous studies that examined the predictive
value of FEV1 decline found that FEV1 decline in-
creases the risk of mortality [4,14].Table 4. LFS at Pretransplantation and at 80 Days, 1 Year, and 2 Y
LFS Category Pretransplantation, n (%) Day 80 Posttransplantation, n (%)*
0 19 (34) 10 (19)
1 35 (63) 36 (68)
2 2 (3) 7 (13)
3 — —
LFS categories: category 0, normal lung function; category 1, mildly abnormal
*LFS calculation was not possible in 2 patients.We did find that DLCO at 1 year remained signif-
icantly lower than pretransplantation values. However,
at 2 years, DLCO continued to improve, with the ma-
jority of patients demonstrating normalized DLCO.
The slower recovery of DLCO at 1 year may be attrib-
uted to the impact of the intensive conditioning regi-
men on gas transfer.
Our study population seems to have more stable
lung function compared with the populations of previ-
ous studies that examined pulmonary function deteri-
oration after myeloablative matched related and
unrelated donor HCT. In fact, patients undergoing
matched related and unrelated donor HCT reportedly
experience a significant decline in FEV1 and FVC
compared with pretransplantation values at 1 and 2
years posttransplantation [3].
Furthermore, the high incidence of pulmonary in-
fections noted in the present study was not associated
with an increased incidence of noninfectious complica-
tions. Indeed, the incidence of late-onset noninfectious
pulmonary complications was 9.7%, similar to the 7%
reported byTomonari et al. [20] in patients who under-
went single CBT but lower than the 16% reported by
Solh et al. [8] in 205 patients who underwent both sin-
gle CBT and dCBT. The median time to the develop-
ment of pulmonary complications after HCT is
approximately 8-12 months, but many cases are diag-
nosed after 1 year posttranslantation. In the present
study, among the 20 patients with a follow-up longer
than 2 years, we found no new cases of pulmonary com-
plications beyond 1 year posttransplantation.ears Posttransplantation
1 Year Posttransplantation, n (%)* 2 Years Posttransplantation, n (%)
9 (25) 9 (45)
21 (58) 10 (50)
6 (17) 1 (5)
— —
; category 2, moderately abnormal; category 3, severely abnormal.
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ratio in patients with PFTs done at 1 and 2 years after
dCBT.Although this improvementmight be explained
by the ‘‘healthy survivor effect’’, it also is possible that in
our population the improved lung function over time
may reflect less pulmonary cGVHD. The strong asso-
ciation between GVHD and lung deterioration is well
known [3,21-23]. Although 43% of our patients were
diagnosed with cGVHD, we found no increased
incidence of late-onset noninfectious pulmonary com-
plications. Thus, it can be speculated that the lung is
not a principal target of cGVHD in dCBT recipients.
In summary, in our population of HCT recipients,
dCBT was not associated with a significant decline in
lung function in the first 2 years after transplantation.
Our results provide preliminary evidence that airflow
decline, considered one of the most common causes
of nonrelapse mortality, is minimal after dCBT. This
may be attributed in part to a decreased severity of
lung cGVHD; however, this hypothesis remains to
be confirmed in a larger prospective study population.
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